Curis, Inc. (NASDAQ:CRIS) Sees Large Drop in Short Interest

Curis, Inc. (NASDAQ:CRIS) saw a large decline in short interest in the month of July. As of July 15th, there was short interest totaling 105,458 shares, a decline of 97.0% from the June 30th total of 3,515,828 shares. Currently, 5.7% of the company’s shares are short sold. Based on an average daily volume of 111,499 shares, the days-to-cover ratio is presently 0.9 days.

Curis Stock Performance

Shares of NASDAQ CRIS traded up $0.22 during trading on Friday, hitting $4.89. 108,491 shares of the company traded hands, compared to its average volume of 482,422. The firm has a market capitalization of $9.54 million, a price-to-earnings ratio of -0.21 and a beta of 3.08. The business’s fifty day moving average is $7.69 and its 200 day moving average is $13.27. Curis has a fifty-two week low of $3.61 and a fifty-two week high of $39.00.

Curis (NASDAQ:CRIS) last issued its earnings results on Tuesday, May 12th. The biotechnology company reported ($25.00) EPS for the quarter, missing the consensus estimate of ($6.53) by ($18.47). On average, analysts predict that Curis will post -25.5 EPS for the current year.

Analyst Upgrades and Downgrades

Several research firms recently commented on CRIS. Zacks Research raised Curis from a “strong sell” rating to a “hold” rating in a research note on Monday, July 13th. Wall Street Zen raised Curis to a “hold” rating in a research note on Saturday, March 28th. Weiss Ratings reissued a “sell (e+)” rating on shares of Curis in a research note on Friday, July 17th. Finally, HC Wainwright reiterated a “buy” rating and issued a $43.00 price objective (up from $17.00) on shares of Curis in a research note on Friday. One research analyst has rated the stock with a Buy rating, one has given a Hold rating and one has issued a Sell rating to the company. Based on data from MarketBeat.com, the stock presently has a consensus rating of “Hold” and a consensus price target of $43.00.

Institutional Investors Weigh In On Curis

Several hedge funds and other institutional investors have recently modified their holdings of the company. Jane Street Group LLC raised its position in shares of Curis by 71.8% during the fourth quarter. Jane Street Group LLC now owns 25,323 shares of the biotechnology company’s stock worth $25,000 after purchasing an additional 10,586 shares during the period. XTX Topco Ltd acquired a new stake in Curis in the 4th quarter valued at $26,000. Focused Wealth Management Inc grew its position in Curis by 83.4% in the 1st quarter. Focused Wealth Management Inc now owns 109,746 shares of the biotechnology company’s stock valued at $60,000 after purchasing an additional 49,900 shares during the period. Squarepoint Ops LLC increased its stake in Curis by 46.2% during the 4th quarter. Squarepoint Ops LLC now owns 86,483 shares of the biotechnology company’s stock valued at $85,000 after purchasing an additional 27,343 shares in the last quarter. Finally, Renaissance Technologies LLC increased its stake in Curis by 52.2% during the 1st quarter. Renaissance Technologies LLC now owns 366,740 shares of the biotechnology company’s stock valued at $201,000 after purchasing an additional 125,823 shares in the last quarter. Institutional investors own 29.97% of the company’s stock.

About Curis

Curis, Inc is a biotechnology company focused on the discovery, development and commercialization of targeted small molecule and antibody therapeutics for the treatment of cancer. The company’s research centers on exploiting key signaling pathways and tumor microenvironment interactions to develop compounds with the potential to address unmet medical needs. Curis’ proprietary pipeline includes multiple programs at various stages of clinical and preclinical development, reflecting its emphasis on innovative oncology drug candidates.

Among Curis’ lead assets is CA-4948, an oral inhibitor of interleukin-1 receptor–associated kinase 4 (IRAK4) partnered with Ikena Oncology, which is being evaluated in hematologic malignancies and solid tumors.